Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research partnership focusing on the development of the former’s TAR DNA-binding protein 43 (TDP-43) small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS).
From 1 December 2024, Dewpoint is set to obtain an upfront payment and is eligible for milestone payments that could total $480m.
The payments are contingent upon achieving specific research and development objectives. If successful, Mitsubishi Tanabe will gain an exclusive option to license the programme, taking over worldwide clinical development and commercialisation responsibilities.
Dewpoint will earn tiered royalties on the net sales of the treatment.
Dewpoint Therapeutics CEO Ameet Nathwani stated: “This partnership underscores the transformative potential of our small molecule condensate modulator which aims to tackle the underlying pathology of ALS and related neurodegenerative diseases via a novel mechanism of action.
“Our c-mod was discovered and developed through Dewpoint’s pioneering condensate-targeted platform. MTPC’s unparalleled expertise in ALS, as the developer of one of the few FDA-approved therapies for sporadic ALS, combined with their global clinical capability and expansive patient network, makes them an ideal partner.”
Dewpoint's expertise in condensate biology led to the discovery of a small molecule that counteracts the mislocalisation of TDP-43.
The protein is a significant factor in neurodegenerative conditions and is notably present in more than 97% of those with ALS.
The company's high-throughput screening approach detects a c-mod that can selectively correct the location of TDP-43, thus restoring its normal function and improving ALS biomarkers in animal models.
The treatment works by correcting condensate dysfunction, known as condensatopathy, which in turn reinstates TDP-43's splicing activity and supports neuronal health.
Gordon Dyal & Co acted as exclusive financial advisor for Dewpoint Therapeutics during the collaboration agreement.
In November 2023, Dewpoint initiated a strategic partnership with Evotec, aimed at advancing its oncology pipeline programmes that include condensate modifying therapeutics.
